Haemonetics Corporation (HAEM) - 10-K Summary
Business Context and Reporting Period
Company: Haemonetics Corporation
Filing Type: Form 10-K (Annual Report)
Period Ended: March 28, 1998
Business Overview: Haemonetics designs, manufactures, and markets automated systems for the collection, processing, and surgical salvage of blood. The company operates in one industry segment. A significant strategic shift occurred during the period with the decision to discontinue its Blood Bank Management Services (BBMS) business to refocus on core medical device manufacturing.
Key Financial Metrics
| Metric | Fiscal 1998 | Fiscal 1997 | Change |
|---|---|---|---|
| Net Revenues | $285.8 million | $303.0 million | (5.7)% |
| Gross Profit | $135.8 million | $159.2 million | (14.7)% |
| Gross Margin | 47.5% | 52.5% | (5.0) pts |
| Operating Income | $6.4 million | $52.5 million | (87.8)% |
| Net Income (Loss) | $(24.8) million | $33.0 million | Loss vs. Profit |
| EPS (Diluted) | $(0.93) | $1.20 | N/A |
| Operating Cash Flow (Continuing) | $32.1 million | $48.2 million | (33.4)% |
| Total Debt | $71.1 million | $29.5 million | +141% |
| Working Capital | $112.8 million | $94.0 million | +19.9% |
Material Changes vs. Prior Period
- Restructuring Charge: The company recorded a non-recurring restructuring charge of $24.5 million in Q3 1998. This included $8.6 million for inventory write-offs, $6.2 million for property/equipment write-downs, and $2.1 million for severance.
- Discontinued Operations: On May 1, 1998, the Board approved the discontinuance of the Blood Bank Management Services (BBMS) business. This resulted in a net loss from discontinued operations of $25.4 million for the year, including an $18.2 million loss on disposal.
- Revenue Decline: Net revenues decreased 5.7% primarily due to a 19.0% drop in equipment sales (attributed to non-recurring 1997 plasma business revenues) and unfavorable currency effects. Disposable sales were down 3.6% reported, but up 6.0% excluding currency.
- Margin Compression: Gross margin declined 5.0 percentage points due to 44% unfavorable currency impact and 56% higher product costs/mix changes.
- Debt Increase: Total debt increased significantly to $71.1 million, driven by the issuance of $40 million in 7.05% Senior Notes in Q3 1998 to repay bank debt and fund general corporate purposes.
Guidance, Outlook, and Risks
- Strategic Direction: Management is refocusing on core competencies: manufacturing medical device equipment and disposables. The company plans to exit the BBMS service business and sell its blood centers.
- Management Changes: John F. White stepped down as CEO/Chairman in January 1998. James L. Peterson was elected CEO/President, and Sir Stuart Burgess became Chairman. New CFO Ronald Ryan was appointed.
- Market Opportunities: The company received FDA clearance for a two-unit red blood cell collection protocol, a technology with an estimated $500 million annual market potential. International approvals in France and Germany were also secured.
- Sales Channel Shift: Haemonetics plans to end its distributor relationship with Bentley Laboratories (Baxter) in the U.S. cardiovascular market and sell directly using its own sales force.
- Risks:
- Year 2000 Compliance: While internal systems are being updated, the company relies on third-party vendors whose compliance is not fully within its control.
- Regulatory: Products are subject to strict FDA and international regulations; delays or failures in approvals could impact growth.
- Competition: Competitors like COBE (Gambro) and Baxter have greater financial resources.
Investor Verification Checklist
- BBMS Divestiture Progress: Verify the timeline and financial terms of the sale of the Blood Bank Management Services centers to ensure the $18.2 million loss on disposal is accurate and that future cash drag is eliminated.
- Restructuring Execution: Confirm that the $24.5 million restructuring charge has resulted in the anticipated cost savings and that the write-offs of inventory and equipment were necessary.
- Two-Unit Red Cell Adoption: Monitor the rate of adoption of the new two-unit red cell collection protocol by U.S. and international blood centers following FDA clearance.
- Direct Sales Transition: Assess the impact of terminating the Bentley Laboratories distribution agreement on U.S. cardiovascular market share and sales efficiency.
- Debt Service: Review the company's ability to service the new $40 million Senior Notes (7.05% interest) given the reduced operating income and cash flow from continuing operations.